Loading…
Xeris Biopharma Holdings, Inc. is projected to rise to $13.04 by 2027, a +56% move from its current price of $8.34. XERS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $8.16 | $8.34 | $8.54 | +0.06% |
| Jul 14 | $8.09 | $8.35 | $8.62 | +0.11% |
| Jul 15 | $8.03 | $8.35 | $8.69 | +0.17% |
| Jul 16 | $7.99 | $8.36 | $8.75 | +0.22% |
| Jul 17 | $7.95 | $8.36 | $8.80 | +0.28% |
| Jul 18 | $7.91 | $8.37 | $8.85 | +0.33% |
| Jul 19 | $7.88 | $8.37 | $8.89 | +0.39% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $7.88 | $8.37 | $8.89 | +0.39% |
| Week 2 | $7.72 | $8.40 | $9.15 | +0.78% |
| Week 3 | $7.60 | $8.44 | $9.36 | +1.17% |
| Week 4 | $7.51 | $8.47 | $9.55 | +1.56% |
| Week 5 | $7.43 | $8.50 | $9.73 | +1.95% |
| Week 6 | $7.37 | $8.54 | $9.89 | +2.35% |
| Week 7 | $7.31 | $8.57 | $10.05 | +2.74% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Xeris Biopharma Holdings, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes therapies for chronic endocrine and neurological diseases in Illinois.
It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism.
The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Xeris Biopharma Holdings, Inc. (XERS) is a Healthcare stock priced at $8.37 per share.
It has a market cap of $1.45B and is ranked 2263.
The year-by-year forecast shows a neutral stance in 2026 with an average price of $8.37, then a bullish trajectory through 2035 with higher averages and progressively larger ROIs, reaching $22.49 in 2030 and $174.86 in 2050. The forecast lists ROIs of 0% in 2026, 56.6% in 2027, 99.2% in 2028, 129.4% in 2029, 168.7% in 2030, 198.2% in 2031, 257.3% in 2032, 361.2% in 2033, 431.8% in 2034, 491.2% in 2035, 998.2% in 2040, and 1989.1% in 2050 with a bullish sentiment from 2027 onward.
A major floor 44.0% below — a decisive break under it would weaken the trend.
The nearest floor, 29.4% below — buyers have tended to step in here.
The nearest ceiling, 7.2% above — a clean break opens room to run.
A major ceiling 29.2% above — clearing it would confirm fresh momentum.
Key XERS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of XERS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $8.59 | Sell | $8.46 | Sell |
| MA 10 | $8.26 | Buy | $8.22 | Buy |
| MA 20 | $7.64 | Buy | $7.77 | Buy |
| MA 50 | $6.80 | Buy | $7.08 | Buy |
| MA 100 | $6.39 | Buy | $6.80 | Buy |
| MA 200 | $7.06 | Buy | $6.60 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 67.88 | Neutral |
| Stoch RSI (14) | 17.46 | Buy |
| CCI (20) | 75.65 | Neutral |
| Williams %R (14) | -29.41 | Info |
| MACD (12,26,9) | 0.08 | Buy |
| ROC (12) | 15.83 | Buy |
| Bollinger %B (20,2) | 0.75 | Neutral |
| Stochastic %K (14) | 70.59 | Neutral |
| TRIX (15) | 1.03 | Buy |
| Awesome (5,34) | 1.53 | Buy |
| Ultimate (7,14,28) | 68.41 | Neutral |
| Momentum (10) | 0.94 | Buy |
| Aroon Osc (25) | 88.00 | Buy |
| Hull MA (9) | 8.78 | Sell |
| ADX (14) | 41.30 | Buy |
| ATR (14) | 0.17 | Info |
The near-term technical picture is bullish in sentiment with RSI14 at 80. The stock sits above both the 50-day and 200-day simple moving averages, with SMA50 at $6.60 and SMA200 at $7.04. Near-term support is at $5.89 and resistance at $8.37, reflecting a current price of $8.37. The 30-day price range runs from $7.38 to $9.49.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.29 | $8.34 | $11.51 | 0% | Neutral | |
| $10.55 | $13.04 | $16.96 | +56% | Bullish | |
| $13.09 | $16.56 | $22.22 | +99% | Bullish | |
| $14.84 | $19.13 | $26.32 | +129% | Bullish | |
| $16.96 | $22.23 | $31.23 | +167% | Bullish | |
| $18.56 | $24.70 | $35.35 | +196% | Bullish | |
| $22.14 | $29.87 | $43.46 | +258% | Bullish | |
| $28.13 | $38.46 | $56.79 | +361% | Bullish | |
| $32.10 | $44.42 | $66.51 | +433% | Bullish | |
| $35.21 | $49.31 | $74.78 | +491% | Bullish | |
| $62.17 | $91.80 | $146.94 | +10.0x | Bullish | |
| $107.89 | $174.20 | $301.89 | +19.9x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $5.29 | $8.34 | $10.21 | +0.00% |
| August 2026 | $7.45 | $8.75 | $10.53 | +4.91% |
| September 2026 | $7.42 | $8.77 | $10.65 | +0.24% |
| October 2026 | $7.65 | $9.08 | $11.12 | +3.57% |
| November 2026 | $7.83 | $9.34 | $11.51 | +2.87% |
| December 2026 | $7.75 | $9.28 | $11.51 | -0.68% |
Click any year to see its month-by-month XERS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, XERS could reach as high as $11.51, with a base case around $8.34 and support toward $5.29 — roughly 0% from $8.34. A consolidation phase looks the most probable path here.
Expect XERS to range from $10.55 to $16.96 through 2027. The $13.04 average target implies a +56% move from current prices. That is up +56% on the projected 2026 average. Momentum favours further upside here.
The XERS price prediction for 2028 points to an average of $16.56 (low $13.09, high $22.22) — a potential gain of +99% on today's $8.34. Buyers look set to stay in control over this stretch.
In 2029, XERS is projected to trade between $14.84 and $26.32, averaging $19.13 — a potential gain of +129% from today's $8.34. That is up +16% on the projected 2028 average. Momentum favours further upside here.
Xeris Biopharma Holdings, Inc.'s 2030 outlook centres on $22.23, within a $16.96 to $31.23 range. That is up +16% on the projected 2029 average. That marks a +167% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, XERS could reach as high as $35.35, with a base case around $24.70 and support toward $18.56 — roughly +196% from $8.34. Momentum favours further upside here.
Expect XERS to range from $22.14 to $43.46 through 2032. The $29.87 average target implies a +258% move from current prices. That is up +21% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The XERS price prediction for 2033 points to an average of $38.46 (low $28.13, high $56.79) — a potential gain of +361% on today's $8.34. Momentum favours further upside here.
In 2034, XERS is projected to trade between $32.10 and $66.51, averaging $44.42 — a potential gain of +433% from today's $8.34. That is up +16% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Xeris Biopharma Holdings, Inc.'s 2035 outlook centres on $49.31, within a $35.21 to $74.78 range. That is up +11% on the projected 2034 average. That marks a +491% change versus current levels. Momentum favours further upside here.
By 2040, XERS could reach as high as $146.94, with a base case around $91.80 and support toward $62.17 — roughly +10.0x from $8.34. Buyers look set to stay in control over this stretch.
Expect XERS to range from $107.89 to $301.89 through 2050. The $174.20 average target implies a +19.9x move from current prices. That is up +90% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in XERS today (≈ 119.904077 XERS) could be worth
$20,887.76
+$19,887.76 (+1989%) by 2050 · US Dollar
Based on the average projected XERS price of $174.2 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in XERSwould be worth at today's price.
$1,000 invested in XERS on Jul 10, 2025 (≈ 189.753321 XERS) would be worth
$1,582.54
+$582.54 (+58.3%) today · 1.58× · US Dollar
Based on a XERS entry price of $5.27 vs. today's $8.34.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $8.28 | $1,007.25 | +0.7% |
| 1 month ago | $6.71 | $1,242.92 | +24.3% |
| 3 months ago | $5.85 | $1,425.64 | +42.6% |
| 6 months ago | $7.87 | $1,059.72 | +6.0% |
| 1 year ago | $5.27 | $1,582.54 | +58.3% |
| All time (5.0y) ago | $3.67 | $2,272.48 | +127.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our XERS forecast.
Our base-case forecast reaches $17.00 around 2029.
Implied market cap at $17.00: $2.93B
The multi-year forecast points to a strong upward path for XERS. By 2030, the average price is forecast at $22.49 with a 168.7% ROI, and by 2040 the average price is $91.92 with a 998.2% ROI. The 2050 forecast shows an average price of $174.86 and a 1989.1% ROI.
Sentiment is bullish across the long horizon, with 2027 onward showing continued upside. These are estimates, not guarantees, and actual results will depend on factors affecting the company’s development programs, regulatory approvals, and market adoption.
Tap a question to reveal the answer.
2030 avg $22.49; min $17.54; max $30.71; ROI 168.7%; sentiment BULLISH.
Forecasts show a bullish trajectory from 2027 onward, with 2027 avg $13.11 and 2030 avg $22.49, plus rising long-term averages through 2050; ROI peaks at 1989.1% by 2050. These are estimates, not guarantees.
The 2035 forecast shows avg $49.48, min $36.58, max $72.19, ROI 491.2%, sentiment BULLISH.
Current price is $8.37; 30-day range is $7.38 to $9.49.
2040 avg $91.92; min $65.11; max $140.58; ROI 998.2%; sentiment BULLISH.
Xeris Biopharma Holdings, Inc. Community Discussion
0Share your Xeris Biopharma Holdings, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.